ClinicalTrials.gg
TerminatedNCT00929409Updated Feb 17, 2012

Controlled Randomised Trial of Ferric Carboxymaltose and Oral Iron to Treat Postpartum Anemia

A Phase 2/3 interventional study of Ferric carboxymaltose and Ferrous sulfate tablets in Anemia, Iron-Deficiency, Puerperal Disorders and Depression, Postpartum, sponsored by Norwegian University of Science and Technology. Terminated at 3 sites in Norway. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2012-02-17.

Sponsored by Norwegian University of Science and Technology · Phase 2/3, Interventional, and Treatment

Why this study was terminated
Stopped prematurely because too few patients were recruited.
Phase
Phase 2/3
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

200 patients with post partum anemia will be randomised to receive either intravenous iron (intervention group) or peroral iron (control group).

The hypothesis is that intravenous iron supplementation is superior to standard peroral iron.

Read the detailed description

The study is a multi center phase 3 trial, comprising 3 medium sized obstetrical units in Norway.

The amount of iron given to the intervention group is calculated according to the modified Ganzoni formula. The control group is given the standard regime of 200 mg ferro sulphate daily. In both groups, treatment start at inclusion, within 48 h of delivery.

The sample size was based on power calculations: About 200 participants are required to detect a difference of 0.5 g/dl between the groups (with 80 % power).

Randomization is performed by use of opaque envelopes. An electronic CRF is applied. Laboratory analysis are provided by a recognized Swedish biochemical laboratory.

Apart from hemoglobin and the common iron parameters, the serum concentration of soluble ferritin receptors will be analyzed, as well as hepcidin levels.

02

Conditions studied

  • Anemia, Iron-Deficiency
  • Puerperal Disorders
  • Depression, Postpartum

Keywords

  • Postpartum anemia, iron-deficiency
03

In context

Anemia, Iron-Deficiency

600 studies on the registry are indexed under Anemia, Iron-Deficiency; 95 are open to participants now.

This study's enrollment of 30 is below the median of 100 across 459 interventional studies indexed under Anemia, Iron-Deficiency.

Browse Anemia, Iron-Deficiency studies →

Lead sponsor

Norwegian University of Science and Technology is the lead sponsor of 495 studies on the registry; 48 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Woman within 48 h post partum
  • level equal or higher than 6.5 g/dl and equal or lower than 8.5 g/dl
  • Able to read and understand the Norwegian language
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Anemia not attributable to iron deficiency
  • for any of the study drugs
  • Treatment with drugs, dietary supplements or natural remedies containing iron
  • condition which in the opinion of the investigator should disqualify the patient from the study
  • Assessed as requiring blood transfusion(s)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    Peroral iron - ferrous sulfate tablets

    Peroral iron given as one tablet of ferrous sulfate 100 mg two times daily

    Drug: Ferrous sulfate tablets

  • Active comparator
    Ferric carboxymaltose

    Intravenous infusion of Ferric Carboxymaltose (Ferinject), the given dose is adapted according to the individual patient's requirement. No other form of iron supplementation is given.

    Drug: Ferric carboxymaltose

Interventions

  • Intravenous infusion of Ferric carboxymaltose in a dose calculated to meet the individual patient's requirements following the Ganzoni formula

    Also known as: Ferinject

  • Standard tablets containing 100 mg ferrous sulfate, 1 tablet two times daily

    Also known as: Duroferon

06

What researchers measure

Primary outcomes

  1. Haemoglobin concentration

    Time frame: 6 weeks

Secondary outcomes

  1. Ferritin

    Time frame: 6 weeks

  2. Fatigue

    Fatigue scale

    Time frame: 6 weeks

  3. Quality of life

    SF-36

    Time frame: 6 weeks

  4. Post partum depression

    Edinburgh Post Partum Depression Scale

    Time frame: 6 weeks

07

Study locations

3 sites
  • Department of Obstetrics, Vestre Viken Hospital Trust
    Drammen, 3004, Norway
  • Sykehuset Innlandet HF
    Lillehammer, N 2609, Norway
  • St Olavs Hospital
    Trondheim, N 7006, Norway
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 17, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00929409
Collaborators
St. Olavs Hospital, Sykehuset Innlandet HF, Sykehuset Buskerud HF
Responsible party
Sponsor
First posted
Jun 29, 2009
Start date
Jun 2009
Primary completion
Jul 2010
Completion
Jul 2010
Last update
Feb 17, 2012

Study contacts

Bjorn Backe, MD PhD
principal investigator · Norwegian University of Science and Technology

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ferric carboxymaltose · Ferrous sulfate

Start the discussion